

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **Guanze Medical Information Industry (Holding) Co., Ltd.**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code : 2427)**

### **PROFIT WARNING AND INSIDE INFORMATION ANNOUNCEMENT UPDATE ON FINANCIAL INFORMATION**

This announcement is made by Guanze Medical Information Industry (Holding) Co., Ltd. (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors of the Company (the “**Directors**”) wishes to inform the shareholders (the “**Shareholders**”) and potential investors of the Company that, based on the preliminary assessment of the Group’s unaudited consolidated management accounts for the twelve months ended 31 December 2025 (the “**Current Period**”) and the information currently available to the Board, the Group is expected to record a net loss attributable to owners of the Company in the range between RMB28.0 million and RMB30.0 million for the Current Period, as compared to a net profit of approximately RMB17.2 million for the twelve months ended 31 December 2024 (the “**Corresponding Period**”).

Such expected loss for the Current Period was mainly attributable to the combined effect of the following factors:

- (1) the decrease in the average selling price and quantity of imaging film products in 2025 as compared to the same period in 2024;
- (2) the decrease in sales from approximately RMB155.7 million in 2024 to approximately RMB88.4 million in 2025; and
- (3) a potential impairment of property, plant and equipment in 2025.

The Company is still in the process of finalising the annual results of the Group for the Current Period. The information contained in this announcement is only based on the preliminary assessment by the Board with reference to the information currently available to the Group and the unaudited consolidated management accounts of the Group for the Current Period, which has not been audited or reviewed by the auditors or the audit committee of the Company and may be subject to adjustments. The Shareholders and potential investors are advised to read carefully the annual results announcement of the Company for Current Period, which is expected to be published by the end of March 2026.

Reference is made to the joint announcements dated 11 February 2026 and 20 February 2026 issued by FUNDE (HONG KONG) INVESTMENT HOLDINGS CO., LIMITED (the “**Offeror**”) and the Company, in relation to, among others, the mandatory unconditional cash offer (the “**Offer**”) by Aristo Securities Limited for and on behalf of the Offeror to acquire all the issued shares of the Company (other than those already owned and/or agreed to be acquired by the Offeror, its ultimate beneficial owners and parties acting in concert with any of them).

The profit warning statements included in this announcement constitute a profit forecast under Rule 10 of the Hong Kong Code on Takeovers and Mergers (the “**Takeovers Code**”) and should therefore be reported on by the Company’s financial advisers and its auditors or accountants in accordance with Rule 10.4 of the Takeovers Code. In view of the requirements of timely disclosure of inside information under Rule 13.09(2)(a) of the Listing Rules and pursuant to Part XIVA of the SFO, the Company is required to issue this announcement as soon as practicable and given the time constraints, the Company has encountered genuine practical difficulties (time-wise or otherwise) in meeting the reporting requirements set out in Rule 10.4 of the Takeovers Code.

Under Rule 10.4 and Practice Note 2 of the Takeovers Code, if a profit forecast is made during an offer period and is first published in an announcement, it must be repeated in full, together with the reports from the Company’s financial advisers and auditors on the said profit forecast, in the next document to be sent to the Shareholders by the Company (the “**Shareholders’ Document**”). However, if the annual results for the Current Period which fall within the ambit of Rule 10.9 of the Takeovers Code and to which the profit warning relates, are published prior to the despatch of the next Shareholders’ Document, the requirements to report on the Profit Warning under Rule 10 of the Takeovers Code will no longer apply.

**WARNING: The profit warning statements in this announcement do not meet the standard required by Rule 10 of the Takeovers Code and have not been reported on in accordance with the Takeovers Code. Shareholders and potential investors should exercise caution in placing reliance on the profit warning statements in assessing the merits and demerits of the Offer. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company. Persons who are in doubt about their positions should consult their professional advisers.**

By Order of the Board  
**Guanze Medical Information Industry (Holding) Co., Ltd.**  
**Meng Xianzhen**  
*Chairman of the Board*

Hong Kong, 18 March 2026

*As at the date of this announcement, the executive Directors are Mr. Meng Xianzhen and Mr. Guo Zhenyu, the non-executive Director is Ms. Meng Cathy, and the independent non-executive Directors are Dr. Zhao Bin, Dr. Chang Shiwang and Dr. Wong Man Hin Raymond.*

*The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.*